

## Clinical Schizophrenia & Related Psychoses

www.clinicalschizophrenia.net

### About Us

The vision of the exciting peer-reviewed quarterly medical journal *Clinical Schizophrenia & Related Psychoses (CS)* is to provide psychiatrists and other healthcare professionals with the latest research and advances in the diagnosis and treatment of schizophrenia and related psychoses. *CS* is a practice-oriented publication focused exclusively on the newest research findings, guidelines, treatment protocols, and clinical trials relevant to patient care.

Distributed free to the 23,642 highest U.S. prescribers of antipsychotic drug therapies, advertising in *CS* is limited to 6 to 8 ads per issue, providing maximum exposure for our select sponsors.

### Editorial Mission

*CS* presents peer-reviewed original research and analysis that deals exclusively with the treatment of schizophrenia and related psychoses and is directly relevant to patient care through:

- ▶ **unique, disease-specific focus** – *CS* is the only clinical publication dedicated entirely to the latest research and advances in the diagnosis and treatment of schizophrenia and related psychoses.
- ▶ **clinically-driven content** – each quarterly issue provides practice-oriented original research results, case reports, comprehensive reviews, current treatment protocols, drug therapy updates, and clinical trial news, as well as meeting highlights from major conferences.
- ▶ **peer-reviewed credibility** – our distinguished Editorial Board is comprised of prominent schizophrenia researchers and clinicians from around the world.
- ▶ **6 to 8 ads per issue limitation** – delivers maximum editorial coverage for our readers and maximum exposure for our select sponsors.

*CS* is indexed in Medline/Pubmed/IndexMedicus, EMBASE and Scopus.

### Circulation

*CS* is distributed free to the 23,642 U.S.-based physicians/prescribers\* who comprise the top seven deciles of all antipsychotic script writers. These high-volume prescribers account for 70% of all antipsychotic scripts written in the U.S. and average 1,113 antipsychotic prescriptions per prescriber per year.

**Clinical Schizophrenia's 23,642 top prescriber readers break out by specialty as follows:**

Psychiatry	13,683	Pediatrics	288
Child/Adolescent Psychiatry	2,891	Geriatric Psychiatry	177
Family/General Medicine	1,752	Nurse Practitioner	2,482
Internal Medicine	1,171	Physician Assistant	284
Neurology	350	Other	564
<b>Total</b>		<b>23,642</b>	

\*Note: 2018 circulation parameters based on the number of antipsychotic script writers in the top seven deciles from IMS Prescriber Profile data. Counts by specialty will vary slightly from issue to issue based on the latest IMS data, but the publisher guarantees distribution to the 23,642 highest antipsychotic prescribers.

### Annual subscription rates for non-qualified readers:

U.S. individual \$90; U.S. institution \$180; International individual \$140; International institution \$240.

Published by Walsh Medical Media

P.O. Box 193

Montvale, NJ 07645

Telephone: 201-391-8411

Fax: 201-391-8447

information@clinicalschizophrenia.net

Publisher: Paul Walsh (201-417-5351)

pwalsh@clinicalschizophrenia.net

Editor: Peter F. Buckley, MD

peter.buckley@vcuhealth.org

Data Card No. 12

Issued: August 1, 2017

Effective Date: January 1, 2018



## Advertising Rates

Advertising rates are effective January 1, 2018 and subject to change upon notification by the publisher.  
**Advertising in CS is limited to 6 to 8 ads per issue, providing maximum exposure for our select sponsors.**

Position	4-Color	B&W
Full Page Run-of-Book	\$10,000	\$5,000
Following Editor's Letter	\$12,500	–
Following Table of Contents	\$12,500	–
Inside Front Cover (2)	\$13,500	–
Back Cover (4)	\$15,000	–

Advertising must be consistent with our editorial mission of providing readers with the latest clinical research and advances in the diagnosis and treatment of schizophrenia and related psychoses. Publisher reserves the right to label any advertisement as such for any ads that contain significant editorial content or that look like editorial pages.

**For split runs, there is an additional commissionable mechanical charge of \$3,500. Premium positions not available to split-run advertisers.**

**Inserts:** Limited availability; check with Publisher. Inserts are billed page for page at the black and white page rate.

**Ad Placement Policy:** Run-of-book advertising in well, front of the publication. Aside from paid positions, ad placement is subject to publisher's discretion.

Agencies receive a 15% commission, contingent on payment within 30 days of the invoice date.

For information regarding CS reprints and advertising opportunities on [www.clinicalschizophrenia.net](http://www.clinicalschizophrenia.net), contact the publisher.

## Issuance and Closings

**First Issue:** April 2007.

**Frequency:** Quarterly.

**Mailing Dates & Class:** Week of issue; standard mail.

Issue	Space Reservation	Key Dates	
		Materials Due	Mail Date
Spring 2018	3/2/18	3/23/18	4/5/18
Summer 2018	6/1/18	6/22/18	7/12/18
Fall 2018	8/31/18	9/21/18	10/4/18
Winter 2019	11/30/18	12/21/18	1/10/19

## Mechanical Requirements

CS is fully illustrated and printed entirely with 4-color processing on the highest quality cover and text stocks.

### Trim Size:

1. CS trims 1/8" from head, foot, side, and gutter trim.
2. Final trim size of the publication is 8-1/8" x 10-3/4".
3. Live matter should be kept to a minimum of 1/2" inside all trimmed edges, and a minimum of 1/2" should be allowed for binding.

**Paper Stock:** Covers – 70# premium Matte Cover;  
 Inside Pages – 50# premium Matte Text.

**Inserts:** Limited availability; check with publisher.

**Type of Binding:** Perfect Bound.

### Electronic Submission of Ads:

CS is produced digitally and printed Direct-to-Plate (DTP).

Below are acceptable formats, in order of preference:

1. PDF – High resolution.
2. EPS/Tiff: All fonts and graphics must be embedded; the files must be saved in high resolution; ads must be complete and sized at 100%.
3. QuarkXpress files with all supporting art/fonts.


All digital ads submitted must be CMYK and must include a press quality proof that specifies if the ad bleeds.

Should corrections be required to digital ads submitted, a minimum production fee of \$100 will be applied.


## Our readers account for 70% of all antipsychotic scripts written!

*Clinical Schizophrenia & Related Psychoses* is distributed free to the 23,642 U.S.-based physicians/prescribers\* who comprise the top seven deciles of all antipsychotic script writers.

These high-volume prescribers account for 70% of all antipsychotic scripts written in the U.S. and average 1,113 antipsychotic prescriptions per prescriber per year.



## Clinical Schizophrenia's 23,642 top prescriber readers break out by these specialties...



## Editorial Mission Statement

*Clinical Schizophrenia & Related Psychoses (CS)* is a peer-reviewed quarterly journal providing psychiatrists and other physicians and healthcare professionals with clinical information relevant to the diagnosis and treatment of people suffering from schizophrenia and other severe mental illnesses. *CS* is a practice-oriented publication covering the latest research, clinical trials, case reports, and treatment advances relevant to the complete treatment of people suffering from schizophrenia and other severe mental illnesses.

## Types of Articles

### Original Contributions

will present results of original clinical research that are relevant to the treatment. Includes a structured abstract.

### Case Reports

will describe treatment or outcome of a single case or a small series of cases. Case reports will focus on important clinical situations, unusual clinical phenomena, new treatments, and new complications. Includes an abstract.

### Comprehensive Reviews

will be a gathering, description, and evaluation of prior publications of key clinical subjects relevant to schizophrenia and related psychoses; includes analysis and conclusions. Contains an abstract.

### Current Clinical Trials

will be descriptions of current ongoing clinical trials, including rationale, enrollment criteria, treatment plans, and anticipated results.

### Translational Medicine

will present basic research that has clinical applications. Coverage will include a description of the development of the basic research and a presentation of the basic research data, as well as data obtained from human samples or patients. An analysis of the implication of the research regarding treatment of schizophrenia and related psychoses will be included. Includes an abstract.

### Clinical Concepts, News and Commentary

will be news that warrants quick dissemination. There will be a focus on new developments, clinical issues that are new or controversial, important news from recent national and international meetings, and brief book reviews.

### Letters to the Editor



## About the Editor

**Peter F. Buckley, MD**  
 Dean, School of Medicine  
 Virginia Commonwealth University (VCU)  
 Richmond, VA

Peter F. Buckley is Dean, School of Medicine, Virginia Commonwealth University (VCU), Richmond, VA.

Dr. Buckley immigrated to America in 1992 after completing his medical degree and postdoctoral training at the University College Dublin School of Medicine in Ireland. His thesis was on the subject of neuroimaging and neurodevelopment in schizophrenia. Prior to joining VCU, Dr. Buckley was dean of the Medical College of Georgia (MCG), Georgia Regents University, and executive vice president for medical affairs and integration. Before his 16-year tenure at MCG, he was professor and vice chair of the psychiatry department at Case Western Reserve University School of Medicine. He also was medical director of Western Reserve Psychiatric Hospital, a role that over time expanded to include serving as medical director for Northcoast Behavioral Healthcare System and its three state inpatient psychiatric facilities in Cleveland and Toledo, Ohio. Previously, Buckley was

co-director of the statewide community service product line for the Ohio Department of Mental Health.

Dr. Buckley conducts research on the neurobiology and treatment of schizophrenia. He is the author of a textbook on psychiatry and has edited seven specialist books on schizophrenia, as well as publishing widely in major psychiatric journals with over 250 book chapters, articles, and abstracts. Dr. Buckley is also Editor-in-Chief of the *Journal of Dual Diagnosis* and is on the editorial board of seven other journals. Dr. Buckley has been a contributor to several expert consensus guidelines and is a federally funded investigator in the treatment of schizophrenia. Dr. Buckley is chair of the schizophrenia spectrum disorders and late life review committee of the National Institute of Mental Health.

Dr. Buckley is on the board of several professional organizations, is a member of the Scientific Board of the National Alliance for the Mentally Ill, is member of a gubernatorial task force for mental health in Georgia, and he is listed in Best Doctors in America. He is the recipient of several awards for his work, including an Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill and the 2006 Georgia Psychiatrist of the Year Award. Dr. Buckley is also the recipient of the American Psychiatric Association Administrative Psychiatric Award for his work on State-University Collaborations.

**Now indexed in  
MEDLINE!**

## Editorial Board

Xavier F. Amador, PhD  
*New York, NY*

Nancy C. Andreasen, MD, PhD  
*Iowa City, IA*

Sabine Bahn, MD, PhD,  
MRCPsych  
*Cambridge, UK*

Ross J. Baldessarini, MD  
*Belmont, MA*

Thomas R.E. Barnes, MD, PhD  
*London, UK*

Francine M. Benes, MD, PhD  
*Belmont, MA*

Nash Boutros, MD  
*Detroit, MI*

Robert W. Buchanan, MD  
*Baltimore, MD*

William T. Carpenter, MD  
*Baltimore, MD*

Robert E. Drake, MD, PhD  
*Lebanon, NH*

Susan M. Essock, PhD  
*New York, NY*

W. Wolfgang Fleischhacker, MD  
*Innsbruck, Austria*

Rohan Ganguli, MD  
*Pittsburgh, PA*

Donald C. Goff, MD  
*New York, NY*

Anthony A. Grace, PhD  
*Pittsburgh, PA*

Michael F. Green, PhD  
*Los Angeles, CA*

Philip D. Harvey, PhD  
*Miami, FL*

David C. Henderson, MD  
*Boston, MA*

Daniel C. Javitt, MD, PhD  
*Orangeburg, NY*

John M. Kane, MD  
*Glen Oaks, NY*

Samuel J. Keith, MD  
*Albuquerque, NM*

Deanna L. Kelly, PharmD, BCPP  
*Baltimore, MD*

Brian Kirkpatrick, MD  
*Reno, NV*

David A. Lewis, MD  
*Pittsburgh, PA*

Jeffrey A. Lieberman, MD  
*New York, NY*

Stephen R. Marder, MD  
*Los Angeles, CA*

Joseph P. McEvoy, MD  
*Butner, NC*

Herbert Y. Meltzer, MD  
*Nashville, TN*

Alexander L. Miller, MD  
*San Antonio, TX*

Kim T. Mueser, PhD  
*Boston, MA*

John W. Newcomer, MD  
*Miami, FL*

Gary Remington, MD, PhD,  
FRCPC  
*Toronto, Canada*

Nina R. Schooler, PhD  
*Washington, DC*

S. Charles Schulz, MD  
*Minneapolis, MN*

Mary V. Seeman, MD  
*Toronto, Canada*

Philip Seeman, MD, PhD  
*Toronto, Canada*

John A. Sweeney, PhD  
*Chicago, IL*

Rajiv Tandon, MD  
*Tallahassee, FL*

Ming T. Tsuang, MD, PhD,  
DSc  
*La Jolla, CA*

Alison Yung, MD, MPM,  
FRANZCP  
*Victoria, Australia*

### Founding Editor

Robert R. Conley, MD